Moleculin公布2025财年全年业绩,确认关键性Miracle试验45名患者中期数据揭盲计划如期推进,预计2026年中完成

美股速递
Mar 19

Moleculin Biotech, Inc. 近日公布了其2025财年全年的财务业绩。公司同时确认,其备受关注的关键性Miracle试验中,针对45名患者的中期数据揭盲计划正按既定时间表顺利推进,预计将在2026年中期完成这一重要节点。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10